Search Results

There are 2266 results for: content related to: Repaglinide in the Management of New-Onset Diabetes Mellitus After Renal Transplantation

  1. Influence of Drugs Interacting with CYP3A4 on the Pharmacokinetics, Pharmacodynamics, and Safety of the Prandial Glucose Regulator Repaglinide

    The Journal of Clinical Pharmacology

    Volume 43, Issue 6, June 2003, Pages: 649–660, Vibeke Hatorp, Kristian T. Hansen and Mikael S. Thomsen

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270003253704

  2. Meglitinide analogues for type 2 diabetes mellitus

    Intervention Review

    The Cochrane Library

    Corri Black, Peter Donnelly, Linda McIntyre, Pamela Royle, Jonathan J Shepherd and Sian Thomas

    Published Online : 18 APR 2007, DOI: 10.1002/14651858.CD004654.pub2

  3. The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 3, September 2008, Pages: 403–411, A Tornio, M Niemi, M Neuvonen, J Laitila, A Kalliokoski, PJ Neuvonen and JT Backman

    Version of Record online : 26 MAR 2008, DOI: 10.1038/clpt.2008.34

  4. Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 4, October 2008, Pages: 488–496, A Kalliokoski, JT Backman, KJ Kurkinen, PJ Neuvonen and M Niemi

    Version of Record online : 16 APR 2008, DOI: 10.1038/clpt.2008.74

  5. Cyclosporine markedly raises the plasma concentrations of repaglinide

    Clinical Pharmacology & Therapeutics

    Volume 78, Issue 4, October 2005, Pages: 388–399, Lauri I. Kajosaari, Mikko Niemi, Mikko Neuvonen, Jouko Laitila, Pertti J. Neuvonen and Janne T. Backman

    Version of Record online : 5 OCT 2005, DOI: 10.1016/j.clpt.2005.07.005

  6. Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide

    The Journal of Clinical Pharmacology

    Volume 48, Issue 3, March 2008, Pages: 311–321, Annikka Kalliokoski, Mikko Neuvonen, Pertti J. Neuvonen and Mikko Niemi

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007311569

  7. Pharmacokinetics of repaglinide in subjects with renal impairment

    Clinical Pharmacology & Therapeutics

    Volume 67, Issue 1, January 2000, Pages: 7–15, Thomas C. Marbury, Jon L. Ruckle, Vibeke Hatorp, Michael P. Andersen, Karin Kramer Nielsen, Won Chin Huang and Poul Strange

    Version of Record online : 5 JAN 2000, DOI: 10.1067/mcp.2000.103973

  8. You have free access to this content
    Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin

    Basic & Clinical Pharmacology & Toxicology

    Volume 97, Issue 4, October 2005, Pages: 249–256, Lauri I. Kajosaari, Jouko Laitila, Pertti J. Neuvonen and Janne T. Backman

    Version of Record online : 20 SEP 2005, DOI: 10.1111/j.1742-7843.2005.pto_157.x

  9. You have full text access to this Open Access content
    Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus

    Journal of Diabetes Investigation

    Volume 3, Issue 3, June 2012, Pages: 302–308, Ryuzo Kawamori, Kohei Kaku, Toshiaki Hanafusa, Daisuke Kashiwabara, Shigeru Kageyama and Nigishi Hotta

    Version of Record online : 22 DEC 2011, DOI: 10.1111/j.2040-1124.2011.00188.x

  10. Repaglinide – prandial glucose regulator: a new class of oral antidiabetic drugs

    Diabetic Medicine

    Volume 15, Issue S4, December 1998, Pages: S28–S36, David R. Owens

    Version of Record online : 19 JUL 2004, DOI: 10.1002/(SICI)1096-9136(1998120)15:4+<S28::AID-DIA748>3.0.CO;2-T

  11. Improvement of insulin sensitivity and β-cell function by nateglinide and repaglinide in type 2 diabetic patients – a randomized controlled double-blind and double-dummy multicentre clinical trial

    Diabetes, Obesity and Metabolism

    Volume 9, Issue 4, July 2007, Pages: 558–565, J. Li, H. Tian, Q. Li, N. Wang, T. Wu, Y. Liu, Z. Ni, H. Yu, J. Liang, R. Luo, Y. Li and L. Huang

    Version of Record online : 18 AUG 2006, DOI: 10.1111/j.1463-1326.2006.00638.x

  12. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 9, September 2009, Pages: 865–873, P. Raskin, A. Lewin, R. Reinhardt, W. Lyness and for the Repaglinide/Metformin Fixed-Dose Combination Study Group

    Version of Record online : 19 MAY 2009, DOI: 10.1111/j.1463-1326.2009.01062.x

  13. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control

    Diabetes, Obesity and Metabolism

    Volume 11, Issue 10, October 2009, Pages: 947–952, P. Raskin, A. Lewin, R. Reinhardt, W. Lyness and for the Repaglinide/Metformin Fixed-Dose Combination Study Group

    Version of Record online : 16 JUN 2009, DOI: 10.1111/j.1463-1326.2009.01069.x

  14. Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans

    Clinical Pharmacology & Therapeutics

    Volume 89, Issue 4, April 2011, Pages: 579–586, J Honkalammi, M Niemi, PJ Neuvonen and JT Backman

    Version of Record online : 2 MAR 2011, DOI: 10.1038/clpt.2010.358

  15. Pharmacokinetics of Repaglinide in Healthy Caucasian and Japanese Subjects

    The Journal of Clinical Pharmacology

    Volume 43, Issue 1, January 2003, Pages: 23–28, Dr. M. S. Thomsen, Dr. D. Chassard, Dr. E. Evène, Dr. K. K. Nielsen and Dr. M. Jørgensen

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270002239702

  16. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide

    Clinical Pharmacology & Therapeutics

    Volume 79, Issue 3, March 2006, Pages: 231–242, Lauri I. Kajosaari, Mikko Niemi, Janne T. Backman and Pertti J. Neuvonen

    Version of Record online : 7 FEB 2006, DOI: 10.1016/j.clpt.2005.11.002

  17. You have free access to this content
    The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range

    British Journal of Clinical Pharmacology

    Volume 66, Issue 6, December 2008, Pages: 818–825, Annikka Kalliokoski, Mikko Neuvonen, Pertti J. Neuvonen and Mikko Niemi

    Version of Record online : 15 AUG 2008, DOI: 10.1111/j.1365-2125.2008.03287.x

  18. Repaglinide: a new short-acting insulinotropic agent for the treatment of Type 2 diabetes

    European Journal of Clinical Investigation

    Volume 29, Issue S2, May 1999, Pages: 30–37, Owens

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2362.1999.00005.x

  19. You have free access to this content
    Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism

    British Journal of Clinical Pharmacology

    Volume 70, Issue 6, December 2010, Pages: 870–880, Jinping Gan, Weiqi Chen, Hong Shen, Ling Gao, Yang Hong, Yuan Tian, Wenying Li, Yueping Zhang, Yuwei Tang, Hongjian Zhang, William Griffith Humphreys and A. David Rodrigues

    Version of Record online : 11 NOV 2010, DOI: 10.1111/j.1365-2125.2010.03772.x

  20. Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone

    Diabetic Medicine

    Volume 21, Issue 4, April 2004, Pages: 329–335, P. Raskin, J. McGill, M. F. Saad, J. M. Cappleman, W. Kaye, N. Khutoryansky and P. M. Hale

    Version of Record online : 5 FEB 2004, DOI: 10.1111/j.1464-5491.2004.01143.x